Lysine Methyltransferase Methyltransferase-Like 13 Regulates Bone Marrow Mesenchymal Stem Cells Osteo-Adipogenic Differentiation And Senescence In Osteoporosis Via The Foxa1/HES-1 Axis
Our bones are constantly being remodeled, with old bone being broken down and new bone being formed. This delicate balance is maintained by specialized cells, including bone marrow mesenchymal stem cells (BMSCs), which can develop into either bone-forming cells (osteocytes) or fat cells (adipocytes). In conditions like osteoporosis, this balance is disrupted, leading to weaker bones.
Recent research has shed light on a key player in this process: a protein called methyltransferase-like 13, or METTL13. Scientists found that in individuals with osteoporosis, METTL13 levels are significantly elevated in aging bone and BMSCs. When METTL13 levels were reduced, the aging process in these cells was reversed.
The study revealed that METTL13 influences the fate of BMSCs by interacting with another protein called Foxa1. This interaction pushes BMSCs to become fat cells rather than bone cells. Interestingly, Foxa1 seems to counteract METTL13’s effects and can even prevent METTL13 from entering the cell’s nucleus, where it exerts its influence.
Further investigation uncovered a crucial pathway: when the entry of Foxa1 into the nucleus is blocked, it leads to a decrease in the expression of a protein called HES-1. This reduction in HES-1 then promotes the formation of fat cells and hinders the formation of bone cells from BMSCs.
These findings highlight a previously unknown molecular pathway, the METTL13-Foxa1-HES-1 axis, which plays a significant role in the aging of BMSCs and their improper differentiation in osteoporosis. This discovery opens up exciting possibilities for developing new therapeutic strategies to combat osteoporosis by targeting this specific pathway.
Source: link to paper